Get started
Author

Afsaneh Panahi

Observed name: Panahi, Afsaneh
ORCID: 0000-0002-3951-5664
Observed ORCID: 0000-0002-3951-5664
OpenAlex ID: A5042955218
Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier
2024 · Sarah Grasedieck, Afsaneh Panahi, et al. · Leukemia · 7
Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia
2025 · Andree-Anne Pelland, Jonathan Isenberg, et al. · Blood · 2
PDF
Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
2024 · Marios Papadimitriou, Marilena Tauro, et al. · Blood · 1
PDF
PA-035 APOBEC3B Promotes Mitochondrial and Inflammatory Adaptation Underlying Proteasome Inhibitor Resistance in Multiple Myeloma
2026 · Faezeh Borzooee, Afsaneh Panahi, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-265 Integrated Spatial and Single-Nucleus Analyses Identify Osteoblast Suppression as a Dominant Feature of Bone Disease in Multiple Myeloma
2026 · Melika Bakharzi, Afsaneh Panahi, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-172 Elevated APOBEC3B Expression Marks Functionally High-Risk Multiple Myeloma with Early Failure of Frontline PI/IMiD Therapy
2026 · Afsaneh Panahi, Faezeh Borzooee, et al. · Clinical Lymphoma Myeloma & Leukemia
Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia
2026 · Hong Li, Timothy Wong, et al. · Leukemia Research
Single-Nucleus Profiling Reveals Aberrant Osteoclast Differentiation in MM
2025 · Melika Bakharzi, Afsaneh Panahi, et al. · Clinical Lymphoma Myeloma & Leukemia
Importance of Re-Induction in Patients with Transplant Eligible Multiple Myeloma Refractory to Frontline Therapy
2025 · Daniela Di Francesco, Heather McPhaden, et al. · Clinical Lymphoma Myeloma & Leukemia
Real-World Outcomes of Patients with Multiple Myeloma Who Received BCMA-Targeted Bispecific Antibodies in British-Columbia
2025 · Andree-Anne Pelland, Jonathan Isenberg, et al. · Clinical Lymphoma Myeloma & Leukemia
APOBEC3B-Driven Metabolic Adaptation Contributes to Bortezomib Resistance in Multiple Myeloma
2025 · Faezeh Borzooee, Hamidreza Galavi, et al. · Clinical Lymphoma Myeloma & Leukemia
P-195 Heterogeneity of Osteoclasts in Multiple Myeloma Revealed by Single Nucleus RNA Sequencing
2024 · Melika Bakharzi, Sarah Grasedieck, et al. · Clinical Lymphoma Myeloma & Leukemia
P-054 Optimizing the Vk*MYC multiple myeloma model to investigate osteolytic bone lesions
2023 · Melika Bakharzi, Elizabeth Fung, et al. · Clinical Lymphoma Myeloma & Leukemia
OA-21 Dysregulated APOBEC3B promotes cell proliferation and DNA damage in multiple myeloma
2023 · Afsaneh Panahi, Sarah Grasedieck, et al. · Clinical Lymphoma Myeloma & Leukemia
P422: Targeting the Wt1mut-mir-193a Transcriptional Axis With Int-1b3, a Novel Lipid Nanoparticle-formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia
2023 · Xining Yang, Kathrin Krowiorz, et al. · HemaSphere
Prolonged Maintenance of Ex Vivo Functional Vk*MYC Multiple Myeloma Cells Allows for in Vitro Manipulation and Subsequent In Vivo Analysis
2022 · Frances E Lock, Afsaneh Panahi, et al. · Blood
Targeting the WT1mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia
2022 · Xining Yang, Kathrin Krowiorz, et al. · Blood
P-150: Identification of misclassified multiple myeloma patient risk subgroups with a novel biological disease stratifier
2022 · Afsaneh Panahi, Sarah Grasedieck, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 19
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type